Pharmaceutical Giant Novartis Reiterates 11 New Plants In US; To Exit India Unit.

Washington DC; February 2026: U.S. President Donald Trump yesterday have said that he has met Vas Narasimhan, the Chief Executive Officer of Swiss drugmaker Novartis at the White House.

Trump, addressing workers at a steel plant in Rome, Georgia yesterday, said Narasimhan told him during the meeting that his company was building 11 plants in the United States as a result of the president’s tariff policies.

“We appreciate the opportunity to update the U.S. government on our progress, including recent groundbreakings for manufacturing and research facilities in North Carolina and California and plans to expand our radioligand therapy manufacturing network with a new site in Florida”, a spokesperson for Novartis have informed the press reporters vide an emailed statement. The statement although did not add any details on the number of facilities planned in the US.

Last year, the Swiss drugmaker said it planned to spend $23 billion to build and expand 10 facilities in the US after the Trump administration threatened to impose drug import duties.

Moreover, Swiss drugmaker Novartis said today early morning (Thursday late evening AST) that it would sell its entire 70.68% stake in its listed Indian unit for 14.46 billion rupees ($159 million). The stake will be acquired by a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners. The companies have also made an offer to purchase an additional 26% stake from Novartis India’s public shareholders, under takeover regulations that mandate such an exercise on purchase of a shareholding of over 25%.

The consortium will offer Novartis India’s public shareholders 860.64 rupees per share, an exchange filing showed, representing a 3.6% premium to its closing price on Thursday. ($1 = 91.0290 Indian rupees).

Team Maverick.